

## Discovery of unprecedented aspartic-protease inhibitors with applications in Alzheimer and other diseases

**Markella Konstantinidou (1), Fandi Sutanto (1), Muhammet Y. Ünver (2), Varsha R. Jumde (2,3), Anna K.H. Hirsch (2,3), Francesca Magari (4), Gerhard Klebe (4), Alexander Dömling (1)**

*(1) Group of Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, A. Deusinglaan 1, 9713 AV, Groningen the Netherlands, (2) Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, 9747 AG Groningen, The Netherlands, (3) Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Department of Drug Design and Optimization, 66123, Saarbrücken, Germany, (4) Department of Pharmaceutical Chemistry, Philipps University Marburg, Marbacher Weg 6, 35032 Marburg, Germany*

Aspartic proteases represent a family of proteins that includes important drug targets. Here we focus on endothiapepsin, a pepsin-like aspartic protease that has been studied excessively as a model enzyme both for elucidating the catalytic mechanism <sup>[a]</sup> and also in the clinical development of renin <sup>[b]</sup> and  $\beta$ -secretase inhibitors <sup>[c]</sup>. The catalytic site of this enzyme, consists of two aspartic acid residues. We designed a novel multicomponent reaction (MCR) scaffold <sup>[d]</sup> with the potential to interact with both acidic residues. A small library of derivatives was synthesized with a straight-forward two-step synthesis and was biologically evaluated with two orthogonal methods. The initial hits were optimized by preparing and docking virtual libraries and a series of new derivatives was synthesized. A co-crystal structure of a small molecule in endothiapepsin was obtained, supporting the design of the scaffold.

**Acknowledgement:** This project has received funding from the European Union's Framework Programme for Research and Innovation Horizon 2020 (2014 – 2020) under the Marie Skłodowska – Curie Grant Agreement No. 675555, Accelerated Early staGe Drug Discovery (AEGIS).

### Bibliographic references:

- <sup>(a)</sup> Coates *et al.* J Am. Chem. Soc. **2008**, 130(23), 7235-37
- <sup>(b)</sup> Veerapandian *et al.* J. Mol. Biol. **1990**, 216(4), 1017-29
- <sup>(c)</sup> Geschwinder *et al.* J. Med. Chem. **2007**, 50(24), 5903-11
- <sup>(d)</sup> Patil *et al.* Synthesis **2016**, 48(08), 1122-30

\* Correspondence: M.Konstantinidou@rug.nl